Metabolic interaction between cyclosporine and sirolimus

Transplantation
Shuang BaiL J Brunner

Abstract

When the immunosuppressants cyclosporine (CsA) and sirolimus (SRL) are co-administered to transplant patients, lower doses are used than when either drug is given alone. Since both drugs share similar transport and metabolic pathways, there is the potential for an interaction leading to unpredictable effects. Furthermore, both drugs affect the activity of cytochrome P450 3A1/2 (CYP3A1/2), the rat parallel to human CYP3A4, and the multidrug transporter P-glycoprotein (Pgp). To clarify the role of metabolic enzymes and membrane transporters involved in the disposition of both drugs, we examined hepatic CYP3A1/2, Pgp, and multidrug resistance gene (mdr) mRNA during chronic therapy with CsA and SRL in salt-depleted rats. Specifically, rats were given intravenous doses of CsA 2.5 mg/kg and SRL 1 mg/kg, alone or in combination, for two weeks via constant rate intravenous infusion. CsA treatment inhibited hepatic CYP3A1/2 protein expression, catalytic activity, and mRNA levels. SRL dosing suppressed CYP3A1/2 protein expression and catalytic activity, without affecting mRNA. With combined dosing, however, there was a much greater reduction. Hepatic Pgp protein levels were elevated after treatment with either drug alone, as well as with...Continue Reading

References

Jan 1, 1986·Annual Review of Medicine·W M Bennett, D J Norman
Jul 1, 1993·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·M IsogaiY Funae
Dec 1, 1995·Therapeutic Drug Monitoring·R W YatscoffJ Zimmerman
Apr 1, 1997·Clinical and Experimental Immunology·S M StepkowskiB D Kahan
Apr 2, 1998·Journal of Pharmaceutical Sciences·A V Kamath, M E Morris
Jul 2, 1998·Kidney International·L J BrunnerD R Koop
Aug 8, 1998·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·J Van AsperenJ H Beijnen
Jul 25, 2000·Journal of Pharmaceutical Sciences·L J Brunner, S Bai
Sep 22, 2000·Molecular Pharmacology·L B LanE G Schuetz
Aug 9, 2003·Drug Development and Industrial Pharmacy·Jinrong LiuLane J Brunner

❮ Previous
Next ❯

Citations

Mar 30, 2007·Cancer Chemotherapy and Pharmacology·Jaime A YáñezNeal M Davies
Mar 6, 2007·Drugs·Joshua J AugustineDonald E Hricik
Mar 28, 2008·Therapeutic Drug Monitoring·Guido FillerUwe Christians
Oct 16, 2012·Expert Review of Gastroenterology & Hepatology·Albert J Czaja
Jun 26, 2014·Expert Opinion on Pharmacotherapy·Albert J Czaja
Nov 1, 2005·Drug Metabolism Reviews·Takaharu Mizutani, Asuka Hattori
Feb 16, 2005·Expert Opinion on Drug Safety·Ali J OlyaeiWilliam M Bennett
Jul 6, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Guido FillerUwe Christians
Feb 15, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Dany AnglicheauEric Thervet
Oct 14, 2005·Transplant International : Official Journal of the European Society for Organ Transplantation·Mariusz NiemczykLeszek Paczek
May 17, 2008·Pediatric Transplantation·Guido FillerUwe Christians
Jun 21, 2005·Transplantation Proceedings·E Dabrowska-ZamojcinM Droździk
Dec 18, 2013·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Keitaro KadonoToshio Teramura
May 25, 2015·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Tamás SolymosiGábor Heltovics
Nov 19, 2011·Immunotherapy·Massimiliano VerouxPierfrancesco Veroux

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.